Ketoconazole

cytochrome P450 family 17 subfamily A member 1 ; Homo sapiens







22 Article(s)
Download
PMID
Title
Pub. Year
#Total Relationships
1 30797030 Spinal cytochrome P450c17 plays a key role in the development of neuropathic mechanical allodynia: Involvement of astrocyte sigma-1 receptors. 2019 May 1 1
2 29049452 HSD3B1 and Response to a Nonsteroidal CYP17A1 Inhibitor in Castration-Resistant Prostate Cancer. 2018 Apr 1 1
3 30154429 The role of ketoconazole in current prostate cancer care. 2018 Oct 2
4 30191523 Ketoconazole plus Lenalidomide in patients with Castration-Resistant Prostate Cancer (CRPC): results of an open-label phase II study. 2018 Dec 1
5 25907623 Commentary on "Comparison of abiraterone acetate versus ketoconazole in patients with metastatic castration resistant prostate cancer refractory to docetaxel." Peer A, Gottfried M, Sinibaldi V, Carducci MA, Eisenberger MA, Sella A, Leibowitz-Amit R, Berger R, Keizman D, Department of Oncology, Rambam Medical Center, Haifa, Israel.: Prostate 2014 Apr;74(4):433-40; doi:10.1002/pros.22765. [Epub 2013 Dec 11]. 2016 May 2
6 25667107 Prospective evaluation of low-dose ketoconazole plus hydrocortisone in docetaxel pre-treated castration-resistant prostate cancer patients. 2015 Jun 1
7 26150586 Strategies to Circumvent Testosterone Surge and Disease Flare in Advanced Prostate Cancer: Emerging Treatment Paradigms. 2015 Jul 3
8 24338986 Comparison of abiraterone acetate versus ketoconazole in patients with metastatic castration resistant prostate cancer refractory to docetaxel. 2014 Apr 2
9 24466356 Ketoconazole inhibits the cellular uptake of anandamide via inhibition of FAAH at pharmacologically relevant concentrations. 2014 2
10 24508512 A-ring modified steroidal azoles retaining similar potent and slowly reversible CYP17A1 inhibition as abiraterone. 2014 Sep 1
11 25042152 Abiraterone acetate in metastatic castration-resistant prostate cancer: a retrospective review of the Princess Margaret experience of (I) low dose abiraterone and (II) prior ketoconazole. 2014 Sep 2
12 25062956 Changing paradigms in management of metastatic Castration Resistant Prostate Cancer (mCRPC). 2014 Jul 25 1
13 22552048 Efficacy of docetaxel-based chemotherapy following ketoconazole in metastatic castration-resistant prostate cancer: implications for prior therapy in clinical trials. 2013 Nov 2
14 23371447 Targeting the adrenal gland in castration-resistant prostate cancer: a case for orteronel, a selective CYP-17 17,20-lyase inhibitor. 2013 Apr 1
15 22971522 Pretreatment neutrophil-to-lymphocyte ratio in metastatic castration-resistant prostate cancer patients treated with ketoconazole: association with outcome and predictive nomogram. 2012 1
16 21094146 Steroid synthesis by primary human keratinocytes; implications for skin disease. 2011 Jan 7 1
17 21712345 Intratumoral androgen biosynthesis in prostate cancer pathogenesis and response to therapy. 2011 Oct 1
18 22066265 [Screening of potential substrates or inhibitors of cytochrome P450 17A1 (CYP17A1) by electrochemical methods]. 2011 Jul-Aug 1
19 20159824 Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. 2010 Mar 20 1
20 19887483 Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancer. 2009 Nov 15 1
21 18985049 CYP17 inhibition as a hormonal strategy for prostate cancer. 2008 Nov 2
22 8325965 Progesterone 16 alpha-hydroxylase activity is catalyzed by human cytochrome P450 17 alpha-hydroxylase. 1993 Jul 1